BridgeMD
New treatment option for Acute Myocardial Infarction (AMI)
Official title Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction
ClinicalTrials.gov ID: NCT07537868
What this study is testing
What is Montelukast 10 Mg Oral Tablet?
Montelukast 10 Mg Oral Tablet is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for acute myocardial infarction (ami).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 75
You may be able to join if
- Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed...
You likely can't join if
- Chronic use of anti-inflammatory drugs
- Severe hepatic or renal impairment
- Hypersensitivity to Montelukast
- Autoimmune or inflammatory diseases
- Cardiogenic shock, severe heart failure or structural complications such as papillary muscle rupture
- Having received cardiopulmonary resuscitation
See the full eligibility criteria
- Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed consent
- Chronic use of anti-inflammatory drugs
- Severe hepatic or renal impairment
- Hypersensitivity to Montelukast
- Autoimmune or inflammatory diseases
- Cardiogenic shock, severe heart failure or structural complications such as papillary muscle rupture
- Having received cardiopulmonary resuscitation
- Severe and inadequately controlled hypertension
- History of myocardial infarction
- Concomitant active bleeding or visceral hemorrhage
- Concomitant malignant tumors, lymphomas, leukemias, or other diseases
- gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug
- Family history of psychiatric disorders
- Pregnancy or lactation
- Participation in another clinical trial
The study team makes the final eligibility decision.
Where it's taking place
- Al Mansurah, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Al Mansurah, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.